Diabetologie und Stoffwechsel 2025; 20(S 01): S98-S99 DOI: 10.1055/s-0045-1807553
Abstracts | DDG 2025
Poster
Posterwalk 15: Sonstige Themen
Early Weight Loss and Cardiometabolic Parameters in Tirzepatide-Treated Participants
in SURMOUNT 1-2
Authors
T Thethi
1
AdventHealth, Translational Research Institute and AdventHealth Diabetes, Obesity
and Endocrinology Institute, Endocrinologist, Orlando, United States
A Kokkinos
2
First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian
University of Athens, Laiko General Hospital, First Department of Propaedeutic Internal
Medicine, Athens, Greece
M McKean-Matthews
3
Eli Lilly and Company, CMH, Indianapolis, United States
C Lee
4
Eli Lilly and Company, Global Medical Affairs Obesity/NILEX, Indianapolis, United
States
L M Neff
5
Eli Lilly and Company, Global Medical Affairs-Obesity, Indianapolis, United States
C Mast
6
Eli Lilly and Company, Global Med Comm-DBU, Indianapolis, United States
A Rodriguez
7
Eli Lilly and Company, Next Generation Incretins (NILEX), Indianapolis, United States
A Stefanski
8
Eli Lilly and Company, CWM Development, Indianapolis, United States
A Bartee
9
Eli Lilly and Company, Next Generation Incretins Development, Indianapolis, United
States
U Lindner
10
Klinikum Chemnitz, Chemnitz, Germany, Internal Medicine and Endocrinology and Diabetology,
Chemnitz, Germany
